MannKind was awarded another patent...
MannKind Assigned Patent
ALEXANDRIA, Va., Sept. 8 -- MannKind, Valencia, Calif., has been assigned a patent (8,258,095) developed by four co-inventors for a "method of controlling glycemia by ultrarapid acting insulin without adjusting an insulin dose for meal content." The co-inventors are Anders Hasager Boss, Princeton, N.J., Richard Petrucci, New Canaan, Conn., Campbell Howard, Yardley, Pa., and Alfred Mann, Valencia, Calif.
The abstract of the patent published by the U.S. Patent and Trademark Office states: "Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day."
The patent application was filed on Aug. 11, 2009 (12/539,499). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,258,095&OS=8,258,095&RS=8,258,095
Written by Satyaban Rath; edited by Hemanta Panigrahi.
For more information about Targeted News Service products and services, please contact: Myron Struck, editor, Targeted News Service LLC, Springfield, Va., 703/304-1897; editor@targetednews.com; http://targetednews.com.
-1099056
http://www.equities.com/news/headline-story?dt=2012-09-08&val=461034&cat=material
